Lundbeck eyes progress in 2022, disappoints compared to consensus

On Wednesday morning, Lundbeck has publicized its full-year financial figures for 2021. Sales of core products grew by 15 percent, but the company is still handing in results slightly below expectations.

Photo: Jens Dresling

On Wednesday, pharmaceutical firm Lundbeck has released its full-year financial figures for 2021.

Already a subscriber? Log in.

Read the whole article

Get access for 14 days for free.
No credit card is needed, and you will not be automatically signed up for a paid subscription after the free trial.

  • Access all locked articles
  • Receive our daily newsletters
  • Access our app
An error has occured. Please try again later.

Get full access for you and your coworkers.

Start a free company trial today

More from MedWatch

Further reading

Related articles

Latest news

See all jobs